Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SYRE
SPYRE THERAPEUTICS, INC.
NASDAQ
$87.25
▲ UP 0.23% (0.20)

KEY STATISTICS

Market Cap$7.57 B
52w High$110.17
52w Low$14.51
Dividend Yield—
Frequency—
P/E-44.74
Volume1.05M
Shares Out.86.84M

COMPANY

LEADERSHIP

Cameron Turtle
CHIEF EXECUTIVE
Cameron Turtle

COMPENSATION 2026

Salary$665,000
Stock Awards$0
Incentive Plan Pay$475,475
All Other Comp.$14,000
Total$6,707,361

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 7, 2016
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
125

PRICE TARGET

Target High$130.00
Target Low$49.00
Target Median$117.50
Target Consensus$106.92

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.—
NOV
3
TUE

SPLIT RECORD

DATETYPERATIO
2023-09-08Reverse1:25

PRICE

$87.25 ▲ UP 0.23% (+$0.20)
OVERLAYS
$86.25$87.00$87.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM87.25

About Spyre Therapeutics, Inc.

https://www.spyre.com ↗

Spyre Therapeutics, a preclinical biotech in Waltham, MA, develops antibody therapies for IBD, including SPY001 (anti-a4ß7), SPY002, and combination treatments targeting inflammatory pathways.

INDUSTRY

Biotechnology

A PRODUCT SPYRE THERAPEUTICS, INC. IS KNOWN FOR

SPY001 (anti-α4β7)
SPY001 (anti-α4β7)

SPY001, Spyre Therapeutics' lead investigational long-acting monoclonal antibody for IBD, is in Phase 2 trials aiming to enable less frequent dosing for conditions like ulcerative colitis.

COMPETITORS

COMPETITOR
ABBV COMPARE
LLY COMPARE
PFE COMPARE
TAK COMPARE

Revenue by Products

IconPRODUCTFY2023
License$0

ETFS HOLDING THIS STOCK

ETFS HOLDING
162
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 2.5M
XSU.TO
0.21% · 1.9M
XBI
1.08% · 1.4M
SCHA
0.15% · 367.8K
FCMO.TO
1.18% · 237.0K
CGMM
0.37% · 142.3K
FTXH
0.89% · 107.0K
LFSC
6.65% · 94.7K
XRS2.DE
0.21% · 67.2K
PTH
1.72% · 52.8K
LABU
0.72% · 47.1K
TMSL
0.14% · 46.7K
DFMC
0.05% · 46.1K
USVM
0.21% · 42.1K
RSSL
0.21% · 35.7K
OP
OPTZ
0.40% · 25.8K
BBSC
0.27% · 22.2K
GSC
0.61% · 19.0K
BKMC
0.17% · 12.7K
ETLZ.DE
0.19% · 4.8K
TILT
0.02% · 4.2K
BBC
0.69% · 3.9K
BIB
0.27% · 3.1K
STXK
0.30% · 2.8K
RFLR
0.22% · 2.4K
MEDI
0.48% · 2.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
64.94%
HOLDERS
299
TOP 12 OF 299 · RANKED BY POSITION SIZE
Fmr LLC
13.0M sh · $1.16B
Blackrock, Inc.
6.5M sh · $577.66M
Perceptive Advisors LLC
4.3M sh · $383.48M
Rtw Investments, LP
4.3M sh · $377.49M
Vanguard Group Inc
4.0M sh · $132.19M
Fairmount Funds Management LLC
4.0M sh · $202.67M
Paradigm Biocapital Advisors LP
3.8M sh · $340.98M
Vr Adviser, LLC
3.7M sh · $185.89M
Capital International Investors
3.5M sh · $114.42M
Tang Capital Management LLC
3.2M sh · $53.63M
State Street Corp
3.1M sh · $271.44M
Price T Rowe Associates Inc /Md/
3.0M sh · $262.87M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR
Albers Jeffrey W.
Sale · 5.0K shares
2026-08-07
★
DIRECTOR
Albers Jeffrey W.
Sale · 8.0K shares
2026-08-07
★
DIRECTOR
Albers Jeffrey W.
Sale · 10.0K shares
2026-08-07
★
DIRECTOR
Albers Jeffrey W.
Purchase · 5.0K shares
2026-08-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OUTPERFORM 4
OVERWEIGHT 1
PEER PERFORM 1
13 GRADES IN THE LAST 12 MONTHS
BTIG BUY Wedbush OUTPERFORM Deutsche Bank BUY Wells Fargo OVERWEIGHT Guggenheim BUY Wolfe Research PEER PERFORM Mizuho OUTPERFORM Citigroup BUY

SECTORS PEERS

PEERPRICE
ABCL$11.54COMPARE
CLDX$39.29COMPARE
IMNM$26.89COMPARE
PHVS$35.65COMPARE
ZYME$29.69COMPARE
NTLA$12.66COMPARE
MAZE$25.79COMPARE
WVE$4.71COMPARE